Author at Microdose

Alexa Julianne

Alexa Julianne works at MAPS to support MDMA-assisted therapy for the treatment of PTSD. With a professional background as a clinical lab scientist, she also has a comprehensive understanding of the many recent and ongoing clinical trials investigating the medical use of all psychedelics. As a writer, she provides research-based educational articles about the therapeutic potential of psychedelics. She is an advocate of psychedelic-assisted therapy for mental health, wellness, and healing and continues to support the advancement of psychedelic clinical research.

Conscious Collective

The viewpoints shared are exclusively those of the contributor and do not necessarily represent the perspectives of Microdose's editorial team or its publishers.

Science

30 Aug 2022

Science Feature: Psilocybin for Headaches

With mounting evidence to support the use of psychedelics in treating serious disorders like PTSD, depression, and anxiety — the sector is now beginning to focus on more highly specialized...

By Alexa Julianne

Science

27 May 2022

Combining Antidepressants and Psilocybin: A Look at the Research

Although it’s too early to say whether patients should taper off antidepressants or combine them with psilocybin treatment, research suggests it may be possible to combine the two...

By Alexa Julianne

Conscious Collective

The viewpoints shared are exclusively those of the contributor and do not necessarily represent the perspectives of Microdose's editorial team or its publishers.

Follow us on social

Latest News

You Might Also Like

26 Nov 2025

Delix Therapeutics Reports Strong Phase Ib Results

Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and...

By Madison Roberts

19 Nov 2025

Childhood Trauma’s Role in Men’s Substance Use Disorders

Childhood trauma leaves a deeper imprint on men’s lives than most realize—and for many, it becomes the hidden engine driving substance use disorders. Research shows that emotional abuse, physical violence,...

By Madison Roberts

19 Nov 2025

Human-Centered AI in Healthcare

Artificial intelligence is redefining modern healthcare, offering powerful tools that enhance diagnosis, expedite drug discovery, and enable truly personalized treatment. As health systems struggle with rising costs, aging populations, and...

By Madison Roberts

16 Oct 2025

Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up

As Big Pharma makes billion-dollar bets in the evolving landscape of neuropsychiatric therapeutics, Enveric Biosciences (NASDAQ: ENVB) is carving out a formidable position — not by chasing headlines, but by...

By Madison Roberts

15 Oct 2025

The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch

Take Enveric Biosciences (NASDAQ: ENVB), a company that’s been flying under the radar while building an IP fortress around a novel class of non-hallucinogenic neuroplastogens. Now, that fortress is being...

By Madison Roberts

10 Oct 2025

After the Billion-Dollar Psychedelic Bet: Who’s Next for Big Pharma?

In the wake of Gilgamesh’s billion-dollar exit, a new wave of companies is emerging, smaller, stealthier, and far more scientifically disciplined than their first-wave predecessors. Their mission: harness the therapeutic...

By Madison Roberts

Alexa Julianne works at MAPS to support MDMA-assisted therapy for the treatment of PTSD. With a professional background as a clinical lab scientist, she also has a comprehensive understanding of the many recent and ongoing clinical trials investigating the medical use of all psychedelics. As a writer, she provides research-based educational articles about the therapeutic potential of psychedelics. She is an advocate of psychedelic-assisted therapy for mental health, wellness, and healing and continues to support the advancement of psychedelic clinical research.

Conscious Collective

The viewpoints shared are exclusively those of the contributor and do not necessarily represent the perspectives of Microdose's editorial team or its publishers.

Conscious Collective

The viewpoints shared are exclusively those of the contributor and do not necessarily represent the perspectives of Microdose's editorial team or its publishers.

Follow us on social

WordPress Ads